New Research Shows Emotional Impact of Low Sexual Desire and Associated Distress on Women Patient Registry Formed to Track Clinical Course of Hypoactive Sexual Desire Disorder

RIDGEFIELD, CT, Feb. 18 /PRNewswire/ -- New findings from a European study show that women with low sexual desire and associated distress experience personal and emotional distress related to the sexual issue. The findings, presented today at the International Society for the Study of Women's Sexual Health (ISSWSH) 2010 Annual Meeting in St. Petersburg, Fla., are based on a survey of 5,098 women with low sexual desire and associated distress. In the study (DESIRE®), many women reported experiencing negative emotions, such as dissatisfaction with their sex life, guilt about sexual difficulties and distress about their sex life, frequently or always during the previous three months.

The DESIRE® (Desire and its Effects on female Sexuality Including Relationships) study identified 7,542 women with low sexual desire and associated distress. Among these women, 5,098 participated and were surveyed on a wide range of attitudes and behaviors relating to their experience of low sexual desire. The reports of their frequency and level of sexual desire over the last 12 months were significantly correlated with reports of their level of distress about their low sexual desire and with each of these negative emotional responses.

The DESIRE study methodology consisted of 65,129 women, ages 18-88 years, from France, Germany, Italy, Spain and the UK, participating in a demographically representative research panel. These women completed an initial screening comprised of the first four questions of the Decreased Sexual Desire Screener® (DSDS®). The DSDS is a five-question diagnostic tool that assists non-expert clinicians in the clinical diagnosis of generalized, acquired Hypoactive Sexual Desire Disorder (HSDD), with more than 85 percent accuracy. In total, 7,542 women answered "yes" to all four questions and did not attribute their desire problem to partner sexual issues or physical trauma and 5,098 women further chose to participate in the in-depth survey.

About the HSDD Patient Registry

To understand the natural course of HSDD in women, the New England Research Institutes in Watertown, Mass., is conducting the first-ever registry in female sexual health. The HSDD Registry for Women is a prospective, multicenter, observational study, which will provide data on the natural history and long-term consequences of HSDD.

"The HSDD Registry for Women is the first sexual medicine registry of its kind to investigate the history and clinical course of generalized, acquired Hypoactive Sexual Desire Disorder in women," said Ray Rosen, Ph.D., Chief Scientist of the New England Research Institutes. "With its in-depth analysis of medical co-morbidities, lifestyle factors and long-term outcomes, we expect the HSDD Registry to address a number of knowledge gaps surrounding HSDD in women."

Nearly one in 10 women report low sexual desire with associated distress, which may be HSDD, an often under-diagnosed condition that is defined as a decrease or lack of sexual desire that causes distress for the patient, may put a strain on relationships with partners, and is not due to the effects of a substance, including medications, or another medical condition.

"Many of the women I see with HSDD experience a high level of guilt and feelings of confusion," said Sheryl Kingsberg, Ph.D., President of ISSWSH, Chief of Behavioral Medicine at University Hospitals Case Medical Center, and professor in reproductive biology at Case Western Reserve University in Cleveland. "They also complain about the distance they feel between themselves and their partner. The emotional impact of HSDD is significant, so I am excited by the growing body of research being presented this year as it provides an in-depth look at this under-recognized but distressing condition."

The study and patient registry are supported by unrestricted grants through Boehringer Ingelheim Pharmaceuticals, Inc.

About the DSDS

The DSDS diagnostic tool consists of five Yes or No questions:

- In the past, was your level of sexual desire/interest good and satisfying to you?

- Has there been a decrease in your level of sexual desire/interest?

- Are you bothered by your decreased level of sexual desire/interest?

- Would you like your level of sexual desire/interest to increase?

In a fifth Yes or No question, women are asked to note any factors from the following list they feel may be contributing to a loss of sexual desire or interest.

- Medications, drugs or alcohol you are currently taking

- Pregnancy, recent childbirth, menopausal symptoms

- Other sexual issues you may be having (pain, decreased arousal or orgasm)

- Your partner's sexual problems

- Dissatisfaction with your relationship or partner

- Stress or fatigue

If a woman answers "Yes" to questions one through four, and "No" to all of the factors in question five, then she may meet the criteria for the diagnosis of generalized, acquired HSDD. However, following the completion of the DSDS, a clinical assessment and review with the clinician is required to confirm the diagnosis of generalized, acquired HSDD.

About Hypoactive Sexual Desire Disorder

Low sexual desire with associated distress is the most commonly reported female sexual complaint. Approximately one in 10 women report low sexual desire with associated distress, which may be HSDD. HSDD is a form of female sexual dysfunction (FSD) and has been recognized as a medical condition for more than 30 years. As defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), HSDD is the persistent lack (or absence) of sexual fantasies or desire for any form of sexual activity causing marked distress or interpersonal difficulty and not better accounted for by another disorder (except another sexual dysfunction), direct physiological effects of a substance (including medications), or a general medical or psychiatric condition. Generalized, acquired HSDD is not limited to certain types of stimulation, situations or partners, and develops only after a period of normal functioning. There has been an unmet need for many women and there is no FDA-approved treatment for HSDD. It can affect women of all ages and at any stage of life.

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and approximately 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of US $17 billion (11.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit http://us.boehringer-ingelheim.com  

Contact:

Lara Crissey

Boehringer Ingelheim Pharmaceuticals, Inc.

203-798-4740

lara.crissey@boehringer-ingelheim.com


SOURCE Boehringer Ingelheim



RELATED LINKS
http://us.boehringer-ingelheim.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.